CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Correction for Durant, CA Cancer J Clin 34 (1) 2-6.
CA Cancer J Clin 1984; 34:201

© 1984 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

CA: A Cancer Journal for Clinicians, Vol 34, 201-201, Copyright © 1984 by American Cancer Society

Correction: Dosage for Nabilone

It has been brought to our attention that the dosage of nabilone was listed incorrectly on page 5 of the January/ February 1984 issue of Ca in the article, "The Problem of Nausea and Vomiting in Modern Cancer Chemotherapy" by John A. Durant, M.D. According to Eli Lilly, sole manufacturer of the drug in this country, the correct dosage is 1-2 milligrams two times a day. Eli Lilly has told Ca that nabilone is not currently commercially available in the United States, but is being used in controlled clinical trials here. Nabilone has been approved for use in other countries and is commercially available in Canada and the United Kingdom; Elli Lilly has alerted its affiliates in those two countries, so that they may in turn alert physicians.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by American Cancer Society.